Bristol-Myers Squibb Demonstrates Commitment To Hematology And Advancing Research And Development Across Multiple Blood Cancers Through Immuno-Oncology Leadership At The 20th Congress Of The European Hematology Association

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced the presentation of clinical research from its hematology portfolio at the 20th Congress of the European Hematology Association (EHA) in Vienna, Austria from June 11-14. Bristol-Myers Squibb will present data for elotuzumab, an investigational immunostimulatory antibody, in relapsed or refractory multiple myeloma; Opdivo (nivolumab), in patients with relapsed or refractory lymphoid malignancies; and Sprycel (dasatinib), in chronic myeloid leukemia.

Help employers find you! Check out all the jobs and post your resume.